Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Conditions:   Osteosarcoma;   Ewing Sarcoma;   Rhabdomyosarcoma;   Relapsed Pediatric Solid Tumor;   Refractory Pediatric Solid Tumor;   Melanoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Neuroblastoma;   Wilms Tumor
Interventions:   Procedure: Cryoablation Therapy;   Drug: Nivolumab;   Drug: Ipilimumab
Sponsors:   Children’s National Research Institute;   Bristol-Myers Squibb
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 1, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments